Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

CheckMate 218, a North American expanded access program (EAP), investigated nivolumab plus ipilimumab in patients with advanced melanoma. Safety and efficacy, including 2-year survival in clinically relevant patient subgroups, are reported. Eligible patients were aged ≥18 years with unresectable sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Hodi, F. Stephen, Chapman, Paul B., Sznol, Mario, Lao, Christopher D., Gonzalez, Rene, Smylie, Michael, Daniels, Gregory A., Thompson, John A., Kudchadkar, Ragini, Sharfman, William, Atkins, Michael, Spigel, David R., Pavlick, Anna, Monzon, Jose, Kim, Kevin B., Ernst, Scott, Khushalani, Nikhil I., van Dijck, Wim, Lobo, Maurice, Hogg, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Articles: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757740/
https://www.ncbi.nlm.nih.gov/pubmed/33234846
http://dx.doi.org/10.1097/CMR.0000000000000708

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7757740/
https://www.ncbi.nlm.nih.gov/pubmed/33234846
http://dx.doi.org/10.1097/CMR.0000000000000708

Ejemplares similares